ABSTRACT
Screening for ethanol use amongst the methadone maintained population has been the subject of some debate over recent years. Of particular concern is the diagnostic value of self report of alcohol use in patients enrolled in a methadone maintenance program (MMTP). This study demonstrates unequivocally that denial of alcohol use by MMTP patients is completely unreliable when compared to urine testing. Conversely, admission of alcohol use by this same population has some value. This study concludes that routine ethanol screening is justified at baseline and at frequent intervals thereafter for all patients enrolled in a methadone maintenance program.
Subject(s)
Alcoholism/diagnosis , Alcoholism/epidemiology , Methadone/therapeutic use , Narcotics/therapeutic use , Opioid-Related Disorders/epidemiology , Opioid-Related Disorders/rehabilitation , Surveys and Questionnaires , Cohort Studies , Humans , Retrospective Studies , Sensitivity and SpecificityABSTRACT
Methadone Maintenance Treatment (MMT) is among the most widely studied treatments for opiate dependence with proven benefits for patients and society. When misused, however, methadone can also be lethal. The issue of methadone diversion is a major concern for all MMT programs. A potential source for such diversion is from those MMT patients who receive daily take home methadone doses. Using a reverse phase high performance liquid chromatography method, seven of the nine patients who were randomly selected to have all of their remaining methadone take home doses (within a 24 hour period) analyzed, returned lower than expected quantities of methadone. This finding suggests the possibility that such patients may have tampered with their daily take home doses. Larger prospective observational studies are clearly needed to test the supposition of this pilot study.
ABSTRACT
Alcohol use among Methadone Maintenance Treatment (MMT) patients poses a major health risk, exacerbates psychopathology, and increases the risk of death by accidental overdose. Despite these factors, screening for alcohol use remains underutilized in the methadone community. Utilizing a self-report screening measure - the Michigan Alcohol Screening Test (MAST) - and consistent with the literature, we found high rates of alcohol problems among MMT patients. Benefits and limitations of using the MAST to screen for alcohol use patterns are discussed.
Subject(s)
Alcoholism/epidemiology , Heroin Dependence/epidemiology , Heroin Dependence/rehabilitation , Mass Screening/methods , Methadone/therapeutic use , Narcotics/therapeutic use , Adult , Alcoholism/psychology , Female , Heroin Dependence/psychology , Humans , Male , Mental Disorders/epidemiology , Mental Disorders/psychologyABSTRACT
Virtually all psychiatric and substance use disorders are associated with sleep disruption. Studies indicate that psychiatric disorders are related closely to chronic insomnia and that psychoactive substances have acute and chronic effects on sleep architecture. Several aspects of sleep are compromised in individuals taking these substances, ranging from difficulty initiating sleep to difficulty maintaining sleep and hypersomnia. Sleep disturbances are apparent in person taking psychoactive drugs or alcohol and have been found to persist long after withdrawing from these drugs. For some, sleep disturbance can be so severe as to reverse treatment success and precipitate relapse to addiction or dependence. There is increasing evidence that primary insomnia without a concurrent psychiatric disorder is a risk factor for later developing substance use disorders. Patients were asked to complete two brief screening tools, the Michigan Alcohol Screening Test and Drug Abuse Screening Test, to examine substance use patterns among patients referred for a variety of sleep complaints in a sleep disorders clinic. We found that patients who demonstrated a variety of sleep complaints were more likely to have alcohol and drug problems than those in the general populations.
Subject(s)
Mass Screening/methods , Referral and Consultation/statistics & numerical data , Sleep Wake Disorders/epidemiology , Sleep Wake Disorders/therapy , Substance Abuse Detection/methods , Substance-Related Disorders/diagnosis , Substance-Related Disorders/epidemiology , Acute Disease , Adult , Chronic Disease , Female , Humans , Male , Middle Aged , Prevalence , Severity of Illness Index , Sleep Wake Disorders/diagnosis , Surveys and QuestionnairesABSTRACT
This study examined the Anesthesia-Assisted Rapid Detoxification (AAROD) procedure and the measurement of withdrawal symptom severity within a 24-hour period. The Clinical Opiate Withdrawal Scale (COWS) was utilized at various time intervals, post detoxification. This study demonstrated that all of the patients who underwent the AAROD procedure had withdrawal symptoms post detoxification in the mild range of severity, unlike like traditional detoxification procedures. Further studies are needed to measure withdrawal symptoms longer than one-day post detoxification and to compare the differences between various detoxification protocols.
